Tvardi Therapeutics, Inc. operates as a biotechnology company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor. Tvardi Therapeutics, Inc. is based in Sugar Land, Texas.